ANNETSAOANNE TSAO8967TSAO, ANNEProfessorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson1400 Holcombe BlvdHouston77030-4008TXAuthorship 1712761Authorship 1730752Authorship 1758721Authorship 1770231Authorship 1777681Authorship 1801071Authorship 1831002Authorship 1833216Authorship 1838671Authorship 1844941Authorship 1881741Authorship 1884506Authorship 1886831Authorship 1887544Authorship 1894691Authorship 1900166Authorship 1903027Authorship 1934294Authorship 195638112869408Tsao AS, McDonnell T, Lam S, Putnam JB, Bekele N, Hong WK, Kurie JMCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive OncologyIncreased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev. 2003 Jul; 12(7):660-4.Cancer Epidemiol Biomarkers Prev2003-07-01T00:00:002003Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies.14710383Karp DD, Tsao AS, Kim ESSeminars in thoracic and cardiovascular surgeryNonsmall-cell lung cancer: chemoprevention studies. Semin Thorac Cardiovasc Surg. 2003 Oct; 15(4):405-20.Semin Thorac Cardiovasc Surg2003-10-01T00:00:002003Nonsmall-cell lung cancer: chemoprevention studies.15195789Tsao AS, Kim ES, Hong WKCA: a cancer journal for cliniciansChemoprevention of cancer. CA Cancer J Clin. 2004 May-Jun; 54(3):150-80.CA Cancer J Clin2004-05-01T00:00:002004Chemoprevention of cancer.16634096Tsao AS, Liu D, Lee JJ, Spitz M, Hong WKCancerSmoking affects treatment outcome in patients with advanced nonsmall cell lung cancer. Cancer. 2006 Jun 01; 106(11):2428-36.Cancer2006-06-01T00:00:002006Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer.17409862Tsao AS, Tang XM, Sabloff B, Xiao L, Shigematsu H, Roth J, Spitz M, Hong WK, Gazdar A, Wistuba IJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerClinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol. 2006 Mar; 1(3):231-9.J Thorac Oncol2006-03-01T00:00:002006Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.17620427Tsao AS, He D, Saigal B, Liu S, Lee JJ, Bakkannagari S, Ordonez NG, Hong WK, Wistuba I, Johnson FMMolecular cancer therapeuticsInhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. Mol Cancer Ther. 2007 Jul; 6(7):1962-72.Mol Cancer Ther2007-07-01T00:00:002007Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion.19735859McAleer MF, Tsao AS, Liao ZInternational journal of radiation oncology, biology, physicsRadiotherapy in malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys. 2009 Oct 01; 75(2):326-37.Int J Radiat Oncol Biol Phys2009-10-01T00:00:002009Radiotherapy in malignant pleural mesothelioma.21437893Chang JY, Komaki R, Lu C, Wen HY, Allen PK, Tsao A, Gillin M, Mohan R, Cox JDCancerPhase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. Cancer. 2011 Oct 15; 117(20):4707-13.Cancer2011-03-22T00:00:002011Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer.21964533Garland LL, Chansky K, Wozniak AJ, Tsao AS, Gadgeel SM, Verschraegen CF, Dasilva MA, Redman M, Gandara DRJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerPhase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509. J Thorac Oncol. 2011 Nov; 6(11):1938-45.J Thorac Oncol2011-11-01T00:00:002011Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.22005546Tsao AS, Heymach JJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerMesothelioma and small cell lung cancer. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1825-6.J Thorac Oncol2011-11-01T00:00:002011Mesothelioma and small cell lung cancer.22247021Ihle NT, Byers LA, Kim ES, Saintigny P, Lee JJ, Blumenschein GR, Tsao A, Liu S, Larsen JE, Wang J, Diao L, Coombes KR, Chen L, Zhang S, Abdelmelek MF, Tang X, Papadimitrakopoulou V, Minna JD, Lippman SM, Hong WK, Herbst RS, Wistuba II, Heymach JV, Powis GJournal of the National Cancer InstituteEffect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012 Feb 08; 104(3):228-39.J Natl Cancer Inst2012-01-13T00:00:002012Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.22586319Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WKCancer discoveryThe BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011 Jun; 1(1):44-53.Cancer Discov2011-06-01T00:00:002011The BATTLE trial: personalizing therapy for lung cancer.23582282Tsao AS, Papadimitrakopoulou VClinical lung cancerThe importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results. Clin Lung Cancer. 2013 Jul; 14(4):311-21.Clin Lung Cancer2013-04-11T00:00:002013The importance of molecular profiling in predicting response to epidermal growth factor receptor family inhibitors in non-small-cell lung cancer: focus on clinical trial results.24166906Blumenschein GR, Saintigny P, Liu S, Kim ES, Tsao AS, Herbst RS, Alden C, Lee JJ, Tang X, Stewart DJ, Kies MS, Fossella FV, Tran HT, Mao L, Hicks ME, Erasmus J, Gupta S, Girard L, Peyton M, Diao L, Wang J, Davis SE, Minna JD, Wistuba I, Hong WK, Heymach JV, Lippman SMClinical cancer research : an official journal of the American Association for Cancer ResearchComprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial. Clin Cancer Res. 2013 Dec 15; 19(24):6967-75.Clin Cancer Res2013-10-28T00:00:002013Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.LeukemiaRadiation OncologyThoracic & Cardiovascular SurgeryThoracic Head & Neck Medical OncologyTranslational Molecular PathologyMD AndersonJOHN VICTORHEYMACHJOHN VICTOR HEYMACH9280HEYMACH, JOHN VICTORProfessorDANIELGOMEZDANIEL GOMEZ9621GOMEZ, DANIELAssociate ProfessorBORISSEPESIBORIS SEPESI9745SEPESI, BORISAssistant ProfessorHAGOP MKANTARJIANHAGOP M KANTARJIAN8501KANTARJIAN, HAGOP MProfessorDAVID CRICEDAVID C RICE8943RICE, DAVID CProfessor10.01430.00697917415research areas5.627280.0166854117coauthor of221.20537.353960similar to11171selected publicationsVASSILIKI APAPADIMITRAKOPOULOUVASSILIKI A PAPADIMITRAKOPOULOU8458PAPADIMITRAKOPOULOU, VASSILIKI AProfessorIGNACIO IVANWISTUBAIGNACIO IVAN WISTUBA9098WISTUBA, IGNACIO IVANProfessorAuthorship 22274813Authorship 2230835Authorship 2253011Authorship 22534010Authorship 2287966Authorship 2288783Authorship 2305201Authorship 2340642Authorship 234237115753462Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, Blumenschein G, Lee JJ, Liu DD, Truong MT, Hong WK, Tran H, Tsao A, Xie D, Ramies DA, Mass R, Seshagiri S, Eberhard DA, Kelley SK, Sandler AJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005 Apr 10; 23(11):2544-55.J Clin Oncol2005-03-07T00:00:002005Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.16640804Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Glisson BS, Lee JJ, Herbst RS, Zinner RGClinical lung cancerAsian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer. 2006 Mar; 7(5):326-31.Clin Lung Cancer2006-03-01T00:00:002006Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program.17496929Carbone M, Albelda SM, Broaddus VC, Flores RM, Hillerdal G, Jaurand MC, Kjaerheim K, Pass HI, Robinson B, Tsao AOncogeneEighth international mesothelioma interest group. Oncogene. 2007 Oct 25; 26(49):6959-67.Oncogene2007-05-14T00:00:002007Eighth international mesothelioma interest group.19255316Tsao AS, Wistuba I, Roth JA, Kindler HLJournal of clinical oncology : official journal of the American Society of Clinical OncologyMalignant pleural mesothelioma. J Clin Oncol. 2009 Apr 20; 27(12):2081-90.J Clin Oncol2009-03-02T00:00:002009Malignant pleural mesothelioma.20587061Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM, Tsao ASHead & neck oncologyMeta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol. 2010 Jun 29; 2:15.Head Neck Oncol2010-06-29T00:00:002010Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC).21062727Garland L, Flores R, Tsao AClinical lung cancerIndividualizing mesothelioma treatment: small steps into a brighter future. Clin Lung Cancer. 2010 Nov 01; 11(6):371-3.Clin Lung Cancer2010-11-01T00:00:002010Individualizing mesothelioma treatment: small steps into a brighter future.21888260Tsao AS, Papadimitrakopoulou VAOncology (Williston Park, N.Y.)The future of NSCLC: molecular profiles guiding treatment decisions. Oncology (Williston Park). 2011 Jun; 25(7):607, 614.Oncology (Williston Park)2011-06-01T00:00:002011The future of NSCLC: molecular profiles guiding treatment decisions.23774390Gomez D, Tsao A, Rice DJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerRecurrence of malignant pleural mesothelioma at the resection borders--local or distant recurrence? J Thorac Oncol. 2013 Jul; 8(7):e65-6.J Thorac Oncol2013-07-01T00:00:002013Recurrence of malignant pleural mesothelioma at the resection borders--local or distant recurrence?24492162Tsao AS, Harun N, Lee JJ, Heymach J, Pisters K, Hong WK, Fujimoto J, Wistuba IClinical lung cancerPhase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma. Clin Lung Cancer. 2014 May; 15(3):197-201.Clin Lung Cancer2013-12-27T00:00:002013Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.Authorship 2454471Authorship 2465501Authorship 2508875Authorship 2517161Authorship 25290710Authorship 2531625Authorship 2553543Authorship 2587381Authorship 2590115Authorship 2590681Authorship 25913710Authorship 2595771Authorship 259705314635084Tsao AS, Kantarjian H, Cortes J, O'Brien S, Talpaz MCancerImatinib mesylate causes hypopigmentation in the skin. Cancer. 2003 Dec 01; 98(11):2483-7.Cancer2003-12-01T00:00:002003Imatinib mesylate causes hypopigmentation in the skin.15139070Tsao AS, Shin DM, Palmer JL, Lee JS, Glisson BSCancerPhase I evaluation of docetaxel and topotecan for patients with advanced solid tumors. Cancer. 2004 May 15; 100(10):2240-5.Cancer2004-05-15T00:00:002004Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors.17954086Rice DC, Stevens CW, Correa AM, Vaporciyan AA, Tsao A, Forster KM, Walsh GL, Swisher SG, Hofstetter WL, Mehran RJ, Roth JA, Liao Z, Smythe WRThe Annals of thoracic surgeryOutcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma. Ann Thorac Surg. 2007 Nov; 84(5):1685-92; discussion 1692-3.Ann Thorac Surg2007-11-01T00:00:002007Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma.19289370Tsao AS, Mehran R, Roth JAClinical lung cancerNeoadjuvant and intrapleural therapies for malignant pleural mesothelioma. Clin Lung Cancer. 2009 Jan; 10(1):36-41.Clin Lung Cancer2009-01-01T00:00:002009Neoadjuvant and intrapleural therapies for malignant pleural mesothelioma.19404214Salmon S, Chen H, Chen S, Herbst R, Tsao A, Tran H, Sandler A, Billheimer D, Shyr Y, Lee JW, Massion P, Brahmer J, Schiller J, Carbone D, Dang TPJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerClassification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen. J Thorac Oncol. 2009 Jun; 4(6):689-96.J Thorac Oncol2009-06-01T00:00:002009Classification by mass spectrometry can accurately and reliably predict outcome in patients with non-small cell lung cancer treated with erlotinib-containing regimen.20036440Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RS, Tsao AS, Tran HT, Dang TPLung cancer (Amsterdam, Netherlands)VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer. 2010 Sep; 69(3):337-40.Lung Cancer2009-12-29T00:00:002009VeriStrat classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab.21264827Sejpal S, Komaki R, Tsao A, Chang JY, Liao Z, Wei X, Allen PK, Lu C, Gillin M, Cox JDCancerEarly findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer. 2011 Jul 01; 117(13):3004-13.Cancer2011-01-24T00:00:002011Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer.22005531Tsao AS, Papadimitrakopoulou VJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerMitotic inhibitors. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1789-90.J Thorac Oncol2011-11-01T00:00:002011Mitotic inhibitors.22819472Amini A, Correa AM, Komaki R, Chang JY, Tsao AS, Roth JA, Swisher SG, Rice DC, Vaporciyan AA, Lin SHThe Annals of thoracic surgeryThe role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy. Ann Thorac Surg. 2012 Sep; 94(3):914-20.Ann Thorac Surg2012-07-21T00:00:002012The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy.23059780Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WKJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerClinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial. J Thorac Oncol. 2012 Nov; 7(11):1645-52.J Thorac Oncol2012-11-01T00:00:002012Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.23328556Falchook GS, Janku F, Tsao AS, Bastida CC, Stewart DJ, Kurzrock RJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerNon-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment. J Thorac Oncol. 2013 Feb; 8(2):e19-20.J Thorac Oncol2013-02-01T00:00:002013Non-small-cell lung cancer with HER2 exon 20 mutation: regression with dual HER2 inhibition and anti-VEGF combination treatment.23442309Tam AL, Kim ES, Lee JJ, Ensor JE, Hicks ME, Tang X, Blumenschein GR, Alden CM, Erasmus JJ, Tsao A, Lippman SM, Hong WK, Wistuba II, Gupta SJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerFeasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial. J Thorac Oncol. 2013 Apr; 8(4):436-42.J Thorac Oncol2013-04-01T00:00:002013Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial.23584298Tsao AS, Liu S, Lee JJ, Alden CM, Blumenschein GR, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WKJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerClinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. J Thorac Oncol. 2013 May; 8(5):658-61.J Thorac Oncol2013-05-01T00:00:002013Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.Authorship 2657131Authorship 2663546Authorship 2684151Authorship 2709596Authorship 271899112358949Tsao AS, Kantarijian H, Talpaz MBritish journal of haematologySTI-571 in chronic myelogenous leukaemia. Br J Haematol. 2002 Oct; 119(1):15-24.Br J Haematol2002-10-01T00:00:002002STI-571 in chronic myelogenous leukaemia.16305830Rice DC, Erasmus JJ, Stevens CW, Vaporciyan AA, Wu JS, Tsao AS, Walsh GL, Swisher SG, Hofstetter WL, Ordonez NG, Smythe WRThe Annals of thoracic surgeryExtended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg. 2005 Dec; 80(6):1988-92; discussion 1992-3.Ann Thorac Surg2005-12-01T00:00:002005Extended surgical staging for potentially resectable malignant pleural mesothelioma.20029443Tsao AS, Roth JA, Herbst RSNature reviews. Clinical oncologySurgery: Future directions in multimodality therapy for NSCLC. Nat Rev Clin Oncol. 2010 Jan; 7(1):10-2.Nat Rev Clin Oncol2010-01-01T00:00:002010Surgery: Future directions in multimodality therapy for NSCLC.23247629Gomez DR, Hong DS, Allen PK, Welsh JS, Mehran RJ, Tsao AS, Liao Z, Bilton SD, Komaki R, Rice DCJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerPatterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma. J Thorac Oncol. 2013 Feb; 8(2):238-45.J Thorac Oncol2013-02-01T00:00:002013Patterns of failure, toxicity, and survival after extrapleural pneumonectomy and hemithoracic intensity-modulated radiation therapy for malignant pleural mesothelioma.24747001Tsao AS, Harun N, Fujimoto J, Devito V, Lee JJ, Kuhn E, Mehran R, Rice D, Moran C, Hong WK, Shen L, Suraokar M, Wistuba IAnnals of diagnostic pathologyElevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma. Ann Diagn Pathol. 2014 Jun; 18(3):140-5.Ann Diagn Pathol2014-02-20T00:00:002014Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma.Authorship 27358510Authorship 2744281Authorship 2747341Authorship 277446Authorship 277512115109537Tsao AS, Kantarjian H, Thomas D, Giles F, Cortes J, Garcia-Manero G, Huh Y, Yang Y, Shen Y, Albitar M, Estey ELeukemia researchC-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome. Leuk Res. 2004 Apr; 28(4):373-8.Leuk Res2004-04-01T00:00:002004C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome.15160360Leong KW, Lee TC, Goh ASCancerImatinib mesylate causes hypopigmentation in the skin. Cancer. 2004 Jun 01; 100(11):2486-7; author reply 2487-8.Cancer2004-06-01T00:00:002004Imatinib mesylate causes hypopigmentation in the skin.18349398Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DHJournal of clinical oncology : official journal of the American Society of Clinical OncologyMolecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008 Mar 20; 26(9):1472-8.J Clin Oncol2008-03-20T00:00:002008Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.21270668Tsao AS, Garland L, Redman M, Kernstine K, Gandara D, Marom EMJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerA practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria. J Thorac Oncol. 2011 Mar; 6(3):598-601.J Thorac Oncol2011-03-01T00:00:002011A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria.23160333Tsao ASJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerMesothelioma. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S399-400.J Thorac Oncol2012-12-01T00:00:002012Mesothelioma.Authorship 2876041Authorship 28917220Authorship 2900467Authorship 2913942Authorship 2924664Authorship 2937045Authorship 2948685Authorship 2948865Authorship 2962611Authorship 3105164Authorship 31236069402940Streckfus CF, Johnson RB, Nick T, Tsao A, Tucci MThe journals of gerontology. Series A, Biological sciences and medical sciencesComparison of alveolar bone loss, alveolar bone density and second metacarpal bone density, salivary and gingival crevicular fluid interleukin-6 concentrations in healthy premenopausal and postmenopausal women on estrogen therapy. J Gerontol A Biol Sci Med Sci. 1997 Nov; 52(6):M343-51.J Gerontol A Biol Sci Med Sci1997-11-01T00:00:001997Comparison of alveolar bone loss, alveolar bone density and second metacarpal bone density, salivary and gingival crevicular fluid interleukin-6 concentrations in healthy premenopausal and postmenopausal women on estrogen therapy.11456925Goodey A, Lavigne JJ, Savoy SM, Rodriguez MD, Curey T, Tsao A, Simmons G, Wright J, Yoo SJ, Sohn Y, Anslyn EV, Shear JB, Neikirk DP, McDevitt JTJournal of the American Chemical SocietyDevelopment of multianalyte sensor arrays composed of chemically derivatized polymeric microspheres localized in micromachined cavities. J Am Chem Soc. 2001 Mar 21; 123(11):2559-70.J Am Chem Soc2001-03-21T00:00:002001Development of multianalyte sensor arrays composed of chemically derivatized polymeric microspheres localized in micromachined cavities.23930212Tsao A, Hui EP, Juergens R, Marur S, Huat TE, Cher GB, Hong RL, Hong WK, Chan ATCancer medicinePhase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer. Cancer Med. 2013 Jun; 2(3):351-9.Cancer Med2013-04-18T00:00:002013Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer.24669013Suraokar MB, Nunez MI, Diao L, Chow CW, Kim D, Behrens C, Lin H, Lee S, Raso G, Moran C, Rice D, Mehran R, Lee JJ, Pass HI, Wang J, Momin AA, James BP, Corvalan A, Coombes K, Tsao A, Wistuba IIAnnals of oncology : official journal of the European Society for Medical OncologyExpression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications. Ann Oncol. 2014 Jun; 25(6):1184-92.Ann Oncol2014-03-24T00:00:002014Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications.24926545Riquelme E, Suraokar MB, Rodriguez J, Mino B, Lin HY, Rice DC, Tsao A, Wistuba IIJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerFrequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma. J Thorac Oncol. 2014 Jul; 9(7):998-1007.J Thorac Oncol2014-07-01T00:00:002014Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.25266654Gomez D, Tsao ASCurrent treatment options in oncologyLocal and systemic therapies for malignant pleural mesothelioma. Curr Treat Options Oncol. 2014 Dec; 15(4):683-99.Curr Treat Options Oncol2014-12-01T00:00:002014Local and systemic therapies for malignant pleural mesothelioma.25442335Chance WW, Rice DC, Allen PK, Tsao AS, Fontanilla HP, Liao Z, Chang JY, Tang C, Pan HY, Welsh JW, Mehran RJ, Gomez DRInternational journal of radiation oncology, biology, physicsHemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. Int J Radiat Oncol Biol Phys. 2015 Jan 01; 91(1):149-56.Int J Radiat Oncol Biol Phys2014-10-25T00:00:002014Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis.25611229Ou SH, Moon J, Garland LL, Mack PC, Testa JR, Tsao AS, Wozniak AJ, Gandara DRJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerSWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol. 2015 Feb; 10(2):387-91.J Thorac Oncol2015-02-01T00:00:002015SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).25800891Krug LM, Kindler HL, Calvert H, Manegold C, Tsao AS, Fennell D, ?hman R, Plummer R, Eberhardt WE, Fukuoka K, Gaafar RM, Lafitte JJ, Hillerdal G, Chu Q, Buikhuisen WA, Lubiniecki GM, Sun X, Smith M, Baas PThe Lancet. OncologyVorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Oncol. 2015 Apr; 16(4):447-56.Lancet Oncol2015-03-20T00:00:002015Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial.25806281Massarelli E, Papadimitrakopoulou V, Welsh J, Tang C, Tsao ASTranslational lung cancer researchImmunotherapy in lung cancer. Transl Lung Cancer Res. 2014 Feb; 3(1):53-63.Transl Lung Cancer Res2014-02-01T00:00:002014Immunotherapy in lung cancer.25837547Tsao ASSeminars in thoracic and cardiovascular surgeryCurrent readings: Window-of-opportunity trials for thoracic malignancies. Semin Thorac Cardiovasc Surg. 2014; 26(4):323-30.Semin Thorac Cardiovasc Surg2014-12-24T00:00:002014Current readings: Window-of-opportunity trials for thoracic malignancies.74Professor10Assistant Professor14Associate Professor16943532Tsao AS, Garden AS, Kies MS, Morrison W, Feng L, Lee JJ, Khuri F, Zinner R, Myers J, Papadimitrakopoulou V, Lewin J, Clayman GL, Ang KK, Glisson BSJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck. J Clin Oncol. 2006 Sep 01; 24(25):4163-9.J Clin Oncol2006-09-01T00:00:002006Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck.19852844Ivanova AV, Ivanov SV, Prudkin L, Nonaka D, Liu Z, Tsao A, Wistuba I, Roth J, Pass HIMolecular cancerMechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects. Mol Cancer. 2009 Oct 24; 8:91.Mol Cancer2009-10-24T00:00:002009Mechanisms of FUS1/TUSC2 deficiency in mesothelioma and its tumorigenic transcriptional effects.19892663Tsao AS, Liu D, Martin J, Tang XM, Lee JJ, El-Naggar AK, Wistuba I, Culotta KS, Mao L, Gillenwater A, Sagesaka YM, Hong WK, Papadimitrakopoulou VCancer prevention research (Philadelphia, Pa.)Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res (Phila). 2009 Nov; 2(11):931-41.Cancer Prev Res (Phila)2009-11-01T00:00:002009Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions.Authorship 842616Authorship 846250Authorship 846260Authorship 846809Authorship 847005Authorship 847153Authorship 847654Authorship 848121Authorship 855965Authorship 859055Authorship 859135Authorship 860134Authorship 860462Authorship 860500Authorship 862084Authorship 862356Authorship 862993Authorship 863455Authorship 863505Authorship 865129Authorship 866981Focus on Alternative and Complementary TherapiesImprovement of clinical response and biomarkers by Camellia sinensis (green tea) extract in patients with high-risk oral premalignant lesions. Focus on Alternative and Complementary Therapies. 15:122-123.Improvement of clinical response and biomarkers by Camellia sinensis (green tea) extract in patients with high-risk oral premalignant lesionsTranslational Lung Cancer ResearchImmunotherapy in lung cancer. Translational Lung Cancer Research. 3:53-63.Immunotherapy in lung cancerInfectious Agents and CancerConcordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners. Infectious Agents and Cancer. 11.Concordance of oral HPV prevalence between patients with oropharyngeal cancer and their partnersLung Cancer. Lung CancerNon-small cell lung cancer. 45-62.Non-small cell lung cancerCommunity OncologyNovel therapies in metastatic head and neck squamous cell carcinoma. Community Oncology. 6:310-316.Novel therapies in metastatic head and neck squamous cell carcinomaCommunity OncologyCetuximab combined with chemotherapy in non-small cell lung cancer. Community Oncology. 7:17-22.Cetuximab combined with chemotherapy in non-small cell lung cancerJournal of Pain and Symptom ManagementDexamethasone for Dyspnea in Cancer Patients. Journal of Pain and Symptom Management. 52:8-16.e1.Dexamethasone for Dyspnea in Cancer PatientsOncologyThe future of NSCLC. Oncology. 25.The future of NSCLCJournal of Thoracic OncologyReply to the letter to the editor entitled a practical guide to measure "all" malignant pleural mesothelioma tumors by modified RECIST criteria?. Journal of Thoracic Oncology. 6:2144-2145.Reply to the letter to the editor entitled a practical guide to measure "all" malignant pleural mesothelioma tumors by modified RECIST criteria?The Lancet OncologyLocal consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy. The Lancet Oncology. 17:1672-1682.Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapyClinical Lung CancerGermline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clinical Lung Cancer. Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung AdenocarcinomaJournal of Thoracic OncologyConsensus report of the 2015 Weinman international conference on mesothelioma. Journal of Thoracic Oncology. 11:1246-1262.Consensus report of the 2015 Weinman international conference on mesotheliomaInternational Journal of Cancer PreventionSuccessful biochemoprevention in a patient with multiple aerodigestive malignancies. International Journal of Cancer Prevention. 2:297-300.Successful biochemoprevention in a patient with multiple aerodigestive malignanciesUnknown JournalPreface. Unknown Journal. xiii.PrefaceNovel and Emerging Agents in NSCLC. 464-478.Novel and Emerging Agents in NSCLCJournal of Thoracic OncologyScientific advances in lung cancer 2015. Journal of Thoracic Oncology. 11:613-638.Scientific advances in lung cancer 2015Tyrosine-kinase inhibitors in oncology. 872-883.Tyrosine-kinase inhibitors in oncologyJournal of Clinical OncologyPhase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma. Journal of Clinical Oncology. 34:2761-2768.Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesotheliomaNew Chemotherapeutic Agents in Lung Cancer. 315-333.New Chemotherapeutic Agents in Lung CancerJournal of Clinical OncologyThe BATTLE-2 study. Journal of Clinical Oncology. 34:3638-3647.The BATTLE-2 study21892101Tsao AS, Liu S, Fujimoto J, Wistuba II, Lee JJ, Marom EM, Charnsangavej C, Fossella FV, Tran HT, Blumenschein GR, Papadimitrakopoulou V, Kies MS, Hong WK, Stewart DJJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerPhase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma. J Thorac Oncol. 2011 Dec; 6(12):2104-11.J Thorac Oncol2011-12-01T00:00:002011Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma.D008654Disorders1775400.668789MesotheliomaD010997Disorders1314670.70062Pleural NeoplasmsD002289Disorders64653060.283287Carcinoma, Non-Small-Cell LungD008175Disorders1353114820.198988Lung NeoplasmsD011799Chemicals & Drugs3569210.67905QuinazolinesAuthorship 9047011Authorship 9049584Authorship 90701025Authorship 90826512Authorship 9109701Authorship 91127910Authorship 91202017Authorship 9124576Authorship 9128305Authorship 9135932Authorship 91497912Authorship 91520811Authorship 9155532Authorship 91562346Authorship 9188465Authorship 9189021Authorship 9202252Authorship 9224079Authorship 92304135Authorship 92351211Authorship 9250575Authorship 9255141Authorship 9272403Authorship 92751513Authorship 9285051Authorship 9296747Authorship 9312613Authorship 9334181Authorship 93683741Authorship 939128526700910Lou Y, Pecot CV, Tran HT, DeVito VJ, Tang XM, Heymach JV, Luthra R, Wistuba II, Zuo Z, Tsao ASClinical lung cancerGermline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma. Clin Lung Cancer. 2016 Mar; 17(2):e5-11.Clin Lung Cancer2015-11-17T00:00:002015Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung Adenocarcinoma.27013409Tsao AS, Scagliotti GV, Bunn PA, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, J?nne PA, Mok TS, Wakelee HA, Pirker R, Mazi?res J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HIJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerScientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016 05; 11(5):613-638.J Thorac Oncol2016-03-22T00:00:002016Scientific Advances in Lung Cancer 2015.27453164Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M, Dogan AU, Gavett S, Gualtieri A, Hassan R, Hesdorffer M, Hirsch FR, Larson D, Mao W, Masten S, Pass HI, Peto J, Pira E, Steele I, Tsao A, Woodard GA, Yang H, Malik SJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerConsensus Report of the 2015 Weinman International Conference on Mesothelioma. J Thorac Oncol. 2016 08; 11(8):1246-1262.J Thorac Oncol2016-08-01T00:00:002016Consensus Report of the 2015 Weinman International Conference on Mesothelioma.27123042Tsao AS, Papadimitrakopoulou V, Lin H, Guo M, Lee JJ, Holsinger FC, Hong WK, Sturgis EMInfectious agents and cancerConcordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners. Infect Agent Cancer. 2016; 11:21.Infect Agent Cancer2016-04-27T00:00:002016Concordance of oral HPV prevalence between patients with oropharyngeal cancer and their partners.27325859Rimner A, Zauderer MG, Gomez DR, Adusumilli PS, Parhar PK, Wu AJ, Woo KM, Shen R, Ginsberg MS, Yorke ED, Rice DC, Tsao AS, Rosenzweig KE, Rusch VW, Krug LMJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. J Clin Oncol. 2016 08 10; 34(23):2761-8.J Clin Oncol2016-06-20T00:00:002016Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma.27330023Hui D, Kilgore K, Frisbee-Hume S, Park M, Tsao A, Delgado Guay M, Lu C, William W, Pisters K, Eapen G, Fossella F, Amin S, Bruera EJournal of pain and symptom managementDexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial. J Pain Symptom Manage. 2016 07; 52(1):8-16.e1.J Pain Symptom Manage2016-06-18T00:00:002016Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial.27480147Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, Goldberg SB, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RSJournal of clinical oncology : official journal of the American Society of Clinical OncologyThe BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 Oct 20; 34(30):3638-3647.J Clin Oncol2016-10-20T00:00:002016The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer.27875070Bekaii-Saab T, Goel S, Dickerson A, Von Roenn J, Thompson MA, Tsao ASJournal of oncology practiceCompetitive Funding Strategies for the Conquer Cancer Foundation of ASCO. J Oncol Pract. 2017 01; 13(1):e62-e67.J Oncol Pract2016-11-22T00:00:002016Competitive Funding Strategies for the Conquer Cancer Foundation of ASCO.27789196Gomez DR, Blumenschein GR, Lee JJ, Hernandez M, Ye R, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Gibbons DL, Karam JA, Kavanagh BD, Tang C, Komaki R, Louie AV, Palma DA, Tsao AS, Sepesi B, William WN, Zhang J, Shi Q, Wang XS, Swisher SG, Heymach JVThe Lancet. OncologyLocal consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016 Dec; 17(12):1672-1682.Lancet Oncol2016-10-24T00:00:002016Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.28599887Tsao AS, Moon J, Wistuba II, Vogelzang NJ, Kalemkerian GP, Redman MW, Gandara DR, Kelly KJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerPhase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Thorac Oncol. 2017 08; 12(8):1299-1308.J Thorac Oncol2017-06-06T00:00:002017Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG S0905).28729154Maio M, Scherpereel A, Calabr? L, Aerts J, Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HLThe Lancet. OncologyTremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol. 2017 09; 18(9):1261-1273.Lancet Oncol2017-07-17T00:00:002017Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.28579481Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DRJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerScientific Advances in Thoracic Oncology 2016. J Thorac Oncol. 2017 08; 12(8):1183-1209.J Thorac Oncol2017-06-01T00:00:002017Scientific Advances in Thoracic Oncology 2016.28972039Zauderer MG, Tsao AS, Dao T, Panageas K, Lai WV, Rimner A, Rusch VW, Adusumilli PS, Ginsberg MS, Gomez D, Rice D, Mehran R, Scheinberg DA, Krug LMClinical cancer research : an official journal of the American Association for Cancer ResearchA Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. Clin Cancer Res. 2017 Dec 15; 23(24):7483-7489.Clin Cancer Res2017-09-28T00:00:002017A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma.28690011Scagliotti GV, Gaafar R, Nowak AK, Reck M, Tsao AS, van Meerbeeck J, Vogelzang NJ, Nakano T, von Wangenheim U, Velema D, Morsli N, Popat SClinical lung cancerLUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma. Clin Lung Cancer. 2017 09; 18(5):589-593.Clin Lung Cancer2017-03-22T00:00:002017LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma.28817374Nelson DB, Rice DC, Niu J, Atay S, Vaporciyan AA, Antonoff M, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Tsao A, Gomez D, Giordano SH, Mehran R, Sepesi BJournal of clinical oncology : official journal of the American Society of Clinical OncologyLong-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis. J Clin Oncol. 2017 Oct 10; 35(29):3354-3362.J Clin Oncol2017-08-17T00:00:002017Long-Term Survival Outcomes of Cancer-Directed Surgery for Malignant Pleural Mesothelioma: Propensity Score Matching Analysis.29191593Reck M, Paz-Ares L, Bidoli P, Cappuzzo F, Dakhil S, Moro-Sibilot D, Borghaei H, Johnson M, Jotte R, Pennell NA, Shepherd FA, Tsao A, Thomas M, Carter GC, Chan-Diehl F, Alexandris E, Lee P, Zimmermann A, Sashegyi A, P?rol MLung cancer (Amsterdam, Netherlands)Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. Lung Cancer. 2017 10; 112:181-187.Lung Cancer2017-08-05T00:00:002017Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.29248169Jeter MD, Gomez D, Nguyen QN, Komaki R, Zhang X, Zhu X, O'Reilly M, Fossella FV, Xu T, Wei X, Wang H, Yang W, Tsao A, Mohan R, Liao ZInternational journal of radiation oncology, biology, physicsSimultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. Int J Radiat Oncol Biol Phys. 2018 03 01; 100(3):730-737.Int J Radiat Oncol Biol Phys2017-11-03T00:00:002017Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.29313814Tsao AS, Lin H, Carter BW, Lee JJ, Rice D, Vaporcyan A, Swisher S, Mehran R, Heymach J, Nilsson M, Fan Y, Nunez M, Diao L, Wang J, Fujimoto J, Wistuba II, Hong WKJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerBiomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. J Thorac Oncol. 2018 02; 13(2):246-257.J Thorac Oncol2017-12-05T00:00:002017Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma.29748017Reck M, Garassino MC, Imbimbo M, Shepherd FA, Socinski MA, Shih JY, Tsao A, Lee P, Winfree KB, Sashegyi A, Cheng R, Varea R, Levy B, Garon ELung cancer (Amsterdam, Netherlands)Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 2018 06; 120:62-69.Lung Cancer2018-03-27T00:00:002018Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting.29371473William WN, Tsao AS, Feng L, Ginsberg LE, Lee JJ, Kies MS, Glisson BS, Kim ESThe oncologistSingle Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas. Oncologist. 2018 05; 23(5):526-e49.Oncologist2018-01-25T00:00:002018Single Arm, Phase II Study of Cisplatin, Docetaxel, and Erlotinib in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinomas.29438696Radovich M, Pickering CR, Felau I, Ha G, Zhang H, Jo H, Hoadley KA, Anur P, Zhang J, McLellan M, Bowlby R, Matthew T, Danilova L, Hegde AM, Kim J, Leiserson MDM, Sethi G, Lu C, Ryan M, Su X, Cherniack AD, Robertson G, Akbani R, Spellman P, Weinstein JN, Hayes DN, Raphael B, Lichtenberg T, Leraas K, Zenklusen JC, Cancer Genome Atlas Network, Fujimoto J, Scapulatempo-Neto C, Moreira AL, Hwang D, Huang J, Marino M, Korst R, Giaccone G, Gokmen-Polar Y, Badve S, Rajan A, Str?bel P, Girard N, Tsao MS, Marx A, Tsao AS, Loehrer PJCancer cellThe Integrated Genomic Landscape of Thymic Epithelial Tumors. Cancer Cell. 2018 02 12; 33(2):244-258.e10.Cancer Cell2018-02-12T00:00:002018The Integrated Genomic Landscape of Thymic Epithelial Tumors.29443651Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, Zon R, Francisco M, Green S, Sherwood S, Harvey RD, Schilsky RLJournal of clinical oncology : official journal of the American Society of Clinical OncologyAmerican Society of Clinical Oncology Statement: Biosimilars in Oncology. J Clin Oncol. 2018 04 20; 36(12):1260-1265.J Clin Oncol2018-02-14T00:00:002018American Society of Clinical Oncology Statement: Biosimilars in Oncology.29208478Milbury K, Engle R, Tsao A, Liao Z, Owens A, Chaoul A, Bruera E, Cohen LJournal of pain and symptom managementPilot Testing of a Brief Couple-Based Mind-Body Intervention for Patients With Metastatic Non-Small Cell Lung Cancer and Their Partners. J Pain Symptom Manage. 2018 03; 55(3):953-961.J Pain Symptom Manage2017-12-05T00:00:002017Pilot Testing of a Brief Couple-Based Mind-Body Intervention for Patients With Metastatic Non-Small Cell Lung Cancer and Their Partners.29211849Nelson DB, Rice DC, Niu J, Atay SM, Vaporciyan AA, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Tsao AS, Gomez DR, Giordano SH, Mehran RJ, Sepesi BEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic SurgeryPredictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma. Eur J Cardiothorac Surg. 2018 05 01; 53(5):960-966.Eur J Cardiothorac Surg2018-05-01T00:00:002018Predictors of trimodality therapy and trends in therapy for malignant pleural mesothelioma.29416870Milbury K, Tsao AS, Liao Z, Owns A, Engle R, Gonzalez EA, Bruera E, Cohen LPilot and feasibility studiesA research protocol for a pilot randomized controlled trial designed to examine the feasibility of a couple-based mind-body intervention for patients with metastatic lung cancer and their partners. Pilot Feasibility Stud. 2018; 4:37.Pilot Feasibility Stud2018-01-24T00:00:002018A research protocol for a pilot randomized controlled trial designed to examine the feasibility of a couple-based mind-body intervention for patients with metastatic lung cancer and their partners.29935841Tsao AS, Gladish GW, Gill RRJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerRevised Modified RECIST Criteria in Malignant Pleural Mesothelioma (Version 1.1): A Step Forward in a Long Race. J Thorac Oncol. 2018 07; 13(7):871-873.J Thorac Oncol2018-07-01T00:00:002018Revised Modified RECIST Criteria in Malignant Pleural Mesothelioma (Version 1.1): A Step Forward in a Long Race.30266660Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SMJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerCurrent and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2018 11; 13(11):1655-1667.J Thorac Oncol2018-09-25T00:00:002018Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.29966799Mutti L, Peikert T, Robinson BWS, Scherpereel A, Tsao AS, de Perrot M, Woodard GA, Jablons DM, Wiens J, Hirsch FR, Yang H, Carbone M, Thomas A, Hassan RJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerScientific Advances and New Frontiers in Mesothelioma Therapeutics. J Thorac Oncol. 2018 09; 13(9):1269-1283.J Thorac Oncol2018-09-01T00:00:002018Scientific Advances and New Frontiers in Mesothelioma Therapeutics.30322867Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G, Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sall? F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J, TCGA Research Network, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi MCancer discoveryIntegrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov. 2018 12; 8(12):1548-1565.Cancer Discov2018-10-15T00:00:002018Integrative Molecular Characterization of Malignant Pleural Mesothelioma.30762130Forde PM, Scherpereel A, Tsao ASCurrent treatment options in oncologyUse of Immune Checkpoint Inhibitors in Mesothelioma. Curr Treat Options Oncol. 2019 02 14; 20(2):18.Curr Treat Options Oncol2019-02-14T00:00:002019Use of Immune Checkpoint Inhibitors in Mesothelioma.Authorship 9468541831067138Gomez DR, Tang C, Zhang J, Blumenschein GR, Hernandez M, Lee JJ, Ye R, Palma DA, Louie AV, Camidge DR, Doebele RC, Skoulidis F, Gaspar LE, Welsh JW, Gibbons DL, Karam JA, Kavanagh BD, Tsao AS, Sepesi B, Swisher SG, Heymach JVJournal of clinical oncology : official journal of the American Society of Clinical OncologyLocal Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study. J Clin Oncol. 2019 06 20; 37(18):1558-1565.J Clin Oncol2019-05-08T00:00:002019Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.21729646Tsao AS, Wei W, Kuhn E, Spencer L, Solis LM, Suraokar M, Lee JJ, Hong WK, Wistuba IIClinical lung cancerImmunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-?) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer. Clin Lung Cancer. 2011 Nov; 12(6):369-74.Clin Lung Cancer2011-05-17T00:00:002011Immunohistochemical overexpression of platelet-derived growth factor receptor-beta (PDGFR-?) is associated with PDGFRB gene copy number gain in sarcomatoid non-small-cell lung cancer.Authorship 9472181Authorship 94744416Authorship 94756322Authorship 948011331099691Tsao AS, Jolly S, Lee JMAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual MeetingUpdates in Local-Regionally Advanced Non-Small Cell Lung Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:553-562.Am Soc Clin Oncol Educ Book2019-05-17T00:00:002019Updates in Local-Regionally Advanced Non-Small Cell Lung Cancer.31103412Scagliotti GV, Gaafar R, Nowak AK, Nakano T, van Meerbeeck J, Popat S, Vogelzang NJ, Grosso F, Aboelhassan R, Jakopovic M, Ceresoli GL, Taylor P, Orlandi F, Fennell DA, Novello S, Scherpereel A, Kuribayashi K, Cedres S, S?rensen JB, Pavlakis N, Reck M, Velema D, von Wangenheim U, Kim M, Barrueco J, Tsao ASThe Lancet. Respiratory medicineNintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Respir Med. 2019 07; 7(7):569-580.Lancet Respir Med2019-05-15T00:00:002019Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial.31125736Gomez DR, Rimner A, Simone CB, Cho BCJ, de Perrot M, Adjei AA, Bueno R, Gill RR, Harpole DH, Hesdorffer M, Hirsch FR, Jackson AA, Pass HI, Rice DC, Rusch VW, Tsao AS, Yorke E, Rosenzweig KJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerThe Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2019 07; 14(7):1172-1183.J Thorac Oncol2019-05-22T00:00:002019The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation.31136816Friedberg JS, Culligan MJ, Tsao AS, Rusch V, Sepesi B, Pass HI, Bueno R, Burt B, Sugarbaker DJ, de Perrot M, Adjei AA, Adusumilli PS, Hirsch FR, Malik SM, Harpole DJJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerA Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce. J Thorac Oncol. 2019 08; 14(8):1343-1353.J Thorac Oncol2019-05-25T00:00:002019A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce.Authorship 948863431179069Nelson DB, Rice DC, Mitchell KG, Tsao AS, Vaporciyan AA, Antonoff MB, Hofstetter WL, Walsh GL, Swisher SG, Roth JA, Gomez DR, Mehran RJ, Sepesi BJournal of thoracic diseaseDefining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database. J Thorac Dis. 2019 Apr; 11(4):1269-1278.J Thorac Dis2019-04-01T00:00:002019Defining the role of adjuvant radiotherapy for malignant pleural mesothelioma: a propensity-matched landmark analysis of the National Cancer Database.Authorship 9509602231260832Tsao MS, Carbone M, Galateau-Salle F, Moreira AL, Nicholson AG, Roden AC, Adjei AA, Aubry MC, Fennell DA, Gomez D, Harpole D, Hesdorffer M, Hirsch FR, Liu G, Malik S, Nowak A, Peikert T, Salgia R, Szlosarek P, Taioli E, Yang H, Tsao A, Mansfield ASJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerPathologic Considerations and Standardization in Mesothelioma Clinical Trials. J Thorac Oncol. 2019 10; 14(10):1704-1717.J Thorac Oncol2019-06-28T00:00:002019Pathologic Considerations and Standardization in Mesothelioma Clinical Trials.Authorship 9518141Authorship 9518491831283845Carbone M, Adusumilli PS, Alexander HR, Baas P, Bardelli F, Bononi A, Bueno R, Felley-Bosco E, Galateau-Salle F, Jablons D, Mansfield AS, Minaai M, de Perrot M, Pesavento P, Rusch V, Severson DT, Taioli E, Tsao A, Woodard G, Yang H, Zauderer MG, Pass HICA: a cancer journal for cliniciansMesothelioma: Scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019 09; 69(5):402-429.CA Cancer J Clin2019-07-08T00:00:002019Mesothelioma: Scientific clues for prevention, diagnosis, and therapy.31280996Tsao A, Nakano T, Nowak AK, Popat S, Scagliotti GV, Heymach JSeminars in oncologyTargeting angiogenesis for patients with unresectable malignant pleural mesothelioma. Semin Oncol. 2019 04; 46(2):145-154.Semin Oncol2019-06-18T00:00:002019Targeting angiogenesis for patients with unresectable malignant pleural mesothelioma.Authorship 953428131386610Tsao AS, Miao J, Wistuba II, Vogelzang NJ, Heymach JV, Fossella FV, Lu C, Velasco MR, Box-Noriega B, Hueftle JG, Gadgeel S, Redman MW, Gandara DR, Kelly KJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Na?ve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905). J Clin Oncol. 2019 10 01; 37(28):2537-2547.J Clin Oncol2019-08-06T00:00:002019Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Na?ve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).Authorship 954166431430846Nelson DB, Rice DC, Mitchell KG, Tsao AS, Gomez DR, Sepesi B, Mehran RJThe Journal of thoracic and cardiovascular surgeryReturn to intended oncologic treatment after surgery for malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2019 09; 158(3):924-929.J Thorac Cardiovasc Surg2019-04-16T00:00:002019Return to intended oncologic treatment after surgery for malignant pleural mesothelioma.Authorship 954677231470129Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB, de Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH, Hesdorffer M, Hirsch FR, Pass HI, Yorke E, Rosenzweig K, Burt B, Fennell DA, Lindwasser W, Malik S, Peikert T, Mansfield AS, Salgia R, Yang H, Rusch VW, Nowak AKJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerRadiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019 10; 14(10):1718-1731.J Thorac Oncol2019-08-27T00:00:002019Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting.Authorship 9617912331778797Lin SH, Lin Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Simon G, Skoulidis F, Chang JY, Jeter MD, Liao Z, Gomez DR, O'Reilly M, Papadimitrakopoulou V, Thall P, Heymach JV, Tsao ASJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerPhase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 2020 02; 15(2):248-257.J Thorac Oncol2019-11-25T00:00:002019Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC.Authorship 9784261432089476Rajaram R, Correa AM, Xu T, Nguyen QN, Antonoff MB, Rice D, Mehran R, Roth J, Walsh G, Swisher S, Hofstetter WL, Vaporciyan A, Cascone T, Tsao AS, Papadimitrakopoulou VA, Gandhi S, Liao Z, Sepesi BClinical lung cancerLocoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clin Lung Cancer. 2020 07; 21(4):e294-e301.Clin Lung Cancer2020-01-27T00:00:002020Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients.Authorship 9794581032193228Cascone T, Sepesi B, Lin HY, Kalhor N, Parra ER, Jiang M, Godoy MCB, Zhang J, Fossella FV, Tsao AS, Lam VK, Lu C, Mott FE, Simon GR, Antonoff MB, Mehran RJ, Rice DC, Behrens C, Weissferdt A, Moran C, Vaporciyan AA, Lee JJ, Swisher SG, Gibbons DL, Wistuba II, William WN, Heymach JVClinical cancer research : an official journal of the American Association for Cancer ResearchA Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 07 15; 26(14):3525-3536.Clin Cancer Res2020-03-19T00:00:002020A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer.Authorship 987471632298162Kris MG, Faivre-Finn C, Kordbacheh T, Chaft J, Luo J, Tsao A, Swisher SAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual MeetingMaking Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now. Am Soc Clin Oncol Educ Book. 2020 Mar; 40:1-12.Am Soc Clin Oncol Educ Book2020-03-01T00:00:002020Making Checkpoint Inhibitors Part of Treatment of Patients With Locally Advanced Lung Cancers: The Time Is Now.Authorship 988173332340682Friedberg JS, Culligan MJ, Tsao AS, Rusch V, Adusumilli PS, Sepesi B, Pass HI, Bueno R, Burt B, Sugarbaker DJ, de Perrot M, Adjei AA, Hirsch FR, Malik SM, Harpole DJJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerReply to Waller et?al. Standardizing Surgical Treatment for Mesothelioma. J Thorac Oncol. 2020 05; 15(5):e75-e77.J Thorac Oncol2020-05-01T00:00:002020Reply to Waller et?al. Standardizing Surgical Treatment for Mesothelioma.Authorship 9892142232389639Hong L, Negrao MV, Dibaj SS, Chen R, Reuben A, Bohac JM, Liu X, Skoulidis F, Gay CM, Cascone T, Mitchell KG, Tran HT, Le X, Byers LA, Sepesi B, Altan M, Elamin YY, Fossella FV, Kurie JM, Lu C, Mott FE, Tsao AS, Rinsurongkawong W, Lewis J, Gibbons DL, Glisson BS, Blumenschein GR, Roarty EB, Futreal PA, Wistuba II, Roth JA, Swisher SG, Papadimitrakopoulou VA, Heymach JV, Lee JJ, Simon GR, Zhang JJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerProgrammed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC. J Thorac Oncol. 2020 09; 15(9):1449-1459.J Thorac Oncol2020-05-08T00:00:002020Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC.Authorship 99310213Authorship 993271532608142Gay CM, Zhou Y, Lee JJ, Tang XM, Lu W, Wistuba II, Ferrarotto R, Gibbons DL, Glisson BS, Kies MS, Simon GR, Heymach JV, Tsao ASThe oncologistA Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma. Oncologist. 2020 10; 25(10):e1457-e1463.Oncologist2020-07-19T00:00:002020A Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma.32621630Milbury K, Li Y, Durrani S, Liao Z, Tsao AS, Carmack C, Cohen L, Bruera EThe oncologistA Mindfulness-Based Intervention as a Supportive Care Strategy for Patients with Metastatic Non-Small Cell Lung Cancer and Their Spouses: Results of a Three-Arm Pilot Randomized Controlled Trial. Oncologist. 2020 11; 25(11):e1794-e1802.Oncologist2020-08-17T00:00:002020A Mindfulness-Based Intervention as a Supportive Care Strategy for Patients with Metastatic Non-Small Cell Lung Cancer and Their Spouses: Results of a Three-Arm Pilot Randomized Controlled Trial.Authorship 9971709Authorship 9974522132816946Chen R, Lee WC, Fujimoto J, Li J, Hu X, Mehran R, Rice D, Swisher SG, Sepesi B, Tran HT, Chow CW, Little LD, Gumbs C, Haymaker C, Heymach JV, Wistuba II, Lee JJ, Futreal PA, Zhang J, Reuben A, Tsao AS, Zhang JClinical cancer research : an official journal of the American Association for Cancer ResearchEvolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. Clin Cancer Res. 2020 10 15; 26(20):5477-5486.Clin Cancer Res2020-08-14T00:00:002020Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment.32798130Augustyn A, Adams DL, He J, Qiao Y, Verma V, Liao Z, Tang CM, Heymach JV, Tsao AS, Lin SHClinical lung cancerGiant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab. Clin Lung Cancer. 2021 05; 22(3):e451-e465.Clin Lung Cancer2020-06-20T00:00:002020Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab.Authorship 10051741133198942Gjyshi O, Xu T, Elhammali A, Boyce-Fappiano D, Chun SG, Gandhi S, Lee P, Chen AB, Lin SH, Chang JY, Tsao A, Gay CM, Zhu XR, Zhang X, Heymach JV, Fossella FV, Lu C, Nguyen QN, Liao ZJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerToxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. J Thorac Oncol. 2021 02; 16(2):269-277.J Thorac Oncol2020-10-22T00:00:002020Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC.Authorship 1006249933268083Tam AL, Papadimitrakopoulou V, Wistuba II, Lee JJ, Ensor JE, Kim ES, Kalhor N, Blumenschein GR, Tsao AS, Heymach JV, Herbst RS, Hicks ME, Hong WK, Gupta SClinical radiologyThe value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials. Clin Radiol. 2021 Feb; 76(2):155.e25-155.e34.Clin Radiol2020-10-22T00:00:002020The value of interventional radiology in clinical trial teams: experience from the BATTLE lung cancer trials.Authorship 1009799633485464Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Jahan T, Antonia S, Oulkhouir Y, Bautista Y, Cornelissen R, Greillier L, Grossi F, Kowalski D, Rodr?guez-Cid J, Aanur P, Oukessou A, Baudelet C, Zalcman GLancet (London, England)First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021 01 30; 397(10272):375-386.Lancet2021-01-21T00:00:002021First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.Authorship 101181021Authorship 10123287Authorship 10123341233603241Cascone T, William WN, Weissferdt A, Leung CH, Lin HY, Pataer A, Godoy MCB, Carter BW, Federico L, Reuben A, Khan MAW, Dejima H, Francisco-Cruz A, Parra ER, Solis LM, Fujimoto J, Tran HT, Kalhor N, Fossella FV, Mott FE, Tsao AS, Blumenschein G, Le X, Zhang J, Skoulidis F, Kurie JM, Altan M, Lu C, Glisson BS, Byers LA, Elamin YY, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Roth JA, Antonoff MB, Kadara H, Haymaker C, Bernatchez C, Ajami NJ, Jenq RR, Sharma P, Allison JP, Futreal A, Wargo JA, Wistuba II, Swisher SG, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Sepesi BNature medicineNeoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. Nat Med. 2021 03; 27(3):504-514.Nat Med2021-02-18T00:00:002021Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.33632775Riely GJ, Neal JW, Camidge DR, Spira AI, Piotrowska Z, Costa DB, Tsao AS, Patel JD, Gadgeel SM, Bazhenova L, Zhu VW, West HL, Mekhail T, Gentzler RD, Nguyen D, Vincent S, Zhang S, Lin J, Bunn V, Jin S, Li S, J?nne PACancer discoveryActivity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial. Cancer Discov. 2021 07; 11(7):1688-1699.Cancer Discov2021-02-25T00:00:002021Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial.33633208Parra ER, Zhai J, Tamegnon A, Zhou N, Pandurengan RK, Barreto C, Jiang M, Rice DC, Creasy C, Vaporciyan AA, Hofstetter WL, Tsao AS, Wistuba II, Sepesi B, Haymaker CScientific reportsIdentification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues. Sci Rep. 2021 02 25; 11(1):4530.Sci Rep2021-02-25T00:00:002021Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues.Authorship 1018191333971174Zhou N, Rice DC, Tsao AS, Lee PP, Haymaker CL, Corsini EM, Antonoff MB, Hofstetter WL, Rajaram R, Roth JA, Swisher SG, Vaporciyan AA, Walsh GL, Mehran RJ, Sepesi BThe Annals of thoracic surgeryExtrapleural Pneumonectomy Versus Pleurectomy/Decortication for Malignant Pleural Mesothelioma. Ann Thorac Surg. 2022 01; 113(1):200-208.Ann Thorac Surg2021-05-08T00:00:002021Extrapleural Pneumonectomy Versus Pleurectomy/Decortication for Malignant Pleural Mesothelioma.Authorship 102746027Authorship 10274771534376553Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, Xu H, Hu S, Sui D, Elamin YY, Le X, Goldberg ME, Murugesan K, Wu CJ, Zhang J, Barreto DS, Robichaux JP, Reuben A, Cascone T, Gay CM, Mitchell KG, Hong L, Rinsurongkawong W, Roth JA, Swisher SG, Lee J, Tsao A, Papadimitrakopoulou V, Gibbons DL, Glisson BS, Singal G, Miller VA, Alexander B, Frampton G, Albacker LA, Shames D, Zhang J, Heymach JVJournal for immunotherapy of cancerOncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. 2021 08; 9(8).J Immunother Cancer2021-08-01T00:00:002021Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer.34377884Tran HT, Lam VK, Elamin YY, Hong L, Colen R, Elshafeey NA, Hassan ISA, Altan M, Blumenschein GR, Rinsurongkawong W, Rivera MJ, Vasquez ME, Carter BW, Byers LE, Tsao AS, Gibbons DL, Fossella F, Glisson BS, Zhang J, Heymach JVJCO precision oncologyClinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling. JCO Precis Oncol. 2021 08; 5.JCO Precis Oncol2021-08-05T00:00:002021Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling.Authorship 10293761634505064Moding EJ, Liu Y, Nabet BY, Chabon JJ, Chaudhuri AA, Hui AB, Bonilla RF, Ko RB, Yoo CH, Gojenola L, Jones CD, He J, Qiao Y, Xu T, Heymach JV, Tsao A, Liao Z, Gomez DR, Das M, Padda SK, Ramchandran KJ, Neal JW, Wakelee HA, Loo BW, Lin SH, Alizadeh AA, Diehn MNature cancerCirculating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer. Nat Cancer. 2020 02; 1(2):176-183.Nat Cancer2020-01-20T00:00:002020Circulating Tumor DNA Dynamics Predict Benefit from Consolidation Immunotherapy in Locally Advanced Non-Small Cell Lung Cancer.Authorship 10301741534550757Elamin YY, Robichaux JP, Carter BW, Altan M, Gibbons DL, Fossella FV, Lam VK, Patel AB, Negrao MV, Le X, Mott FE, Zhang J, Feng L, Blumenschein G, Tsao AS, Heymach JVJournal of clinical oncology : official journal of the American Society of Clinical OncologyPoziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial. J Clin Oncol. 2022 03 01; 40(7):702-709.J Clin Oncol2021-09-22T00:00:002021Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial.Authorship 1034261634787022Lazar Neto F, Sousa LG, Lewis WE, Glisson B, Heymach JV, Tsao AS, Ferrarotto RJournal of intensive care medicineOutcomes of Critically Ill Lung Cancer Patients Initiating Targeted Therapy or Immunotherapy in the Intensive Care Unit: A Single-Center Report. J Intensive Care Med. 2022 Aug; 37(8):1055-1059.J Intensive Care Med2021-11-17T00:00:002021Outcomes of Critically Ill Lung Cancer Patients Initiating Targeted Therapy or Immunotherapy in the Intensive Care Unit: A Single-Center Report.Authorship 1035665734918546Riely GJ, Ahn MJ, Felip E, Ramalingam SS, Smit EF, Tsao AS, Alcasid A, Usari T, Wissel PS, Wilner KD, Johnson BEFuture oncology (London, England)Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small?cell lung cancer: phase II PHAROS study design. Future Oncol. 2022 Mar; 18(7):781-791.Future Oncol2021-12-17T00:00:002021Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small?cell lung cancer: phase II PHAROS study design.Authorship 103615615Authorship 1036600134985934Tsao AS, Pass HI, Rimner A, Mansfield ASJournal of clinical oncology : official journal of the American Society of Clinical OncologyNew Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options. J Clin Oncol. 2022 02 20; 40(6):681-692.J Clin Oncol2022-01-05T00:00:002022New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.34957368Le X, Hong L, Hensel C, Chen R, Kemp H, Coleman N, Ciunci CA, Liu SV, Negrao MV, Yen J, Xia X, Scheuenpflug J, Stroh C, Juraeva D, Tsao A, Hong D, Raymond V, Paik P, Zhang J, Heymach JVJCO precision oncologyLandscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping. JCO Precis Oncol. 2021; 5.JCO Precis Oncol2021-12-13T00:00:002021Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell Lung Cancer Harboring MET Exon 14 Skipping.Authorship 10394519Authorship 104021718Authorship 10406271Authorship 10408641735124183Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, Nowak AK, Fujimoto N, Tsao AS, Mansfield AS, Popat S, Zhang X, Hu N, Balli D, Spires T, Zalcman GAnnals of oncology : official journal of the European Society for Medical OncologyFirst-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. Ann Oncol. 2022 05; 33(5):488-499.Ann Oncol2022-02-03T00:00:002022First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.35190177Sepesi B, Zhou N, William WN, Lin HY, Leung CH, Weissferdt A, Mitchell KG, Pataer A, Walsh GL, Rice DC, Roth JA, Mehran RJ, Hofstetter WL, Antonoff MB, Rajaram R, Negrao MV, Tsao AS, Gibbons DL, Lee JJ, Heymach JV, Vaporciyan AA, Swisher SG, Cascone TThe Journal of thoracic and cardiovascular surgerySurgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer. J Thorac Cardiovasc Surg. 2022 11; 164(5):1327-1337.J Thorac Cardiovasc Surg2022-01-23T00:00:002022Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer.35172522Tsao AS, Wistuba I, Xia D, Byers L, Diao L, Wang J, Papadimitrakopoulou V, Tang X, Lu W, Kadara H, Grigoryev DN, Selvan ME, G?m?s ZH, Tan Z, Zhang S, Nilsson M, Heymach JVJCO precision oncologyGermline and Somatic Smoothened Mutations in Non-Small-Cell Lung Cancer Are Potentially Responsive to Hedgehog Inhibitor Vismodegib. JCO Precis Oncol. 2017 Nov; 1:1-10.JCO Precis Oncol2017-11-01T00:00:002017Germline and Somatic Smoothened Mutations in Non-Small-Cell Lung Cancer Are Potentially Responsive to Hedgehog Inhibitor Vismodegib.35051703Lin SH, Lin HY, Verma V, Xu-Welliver M, Thall PF, Yao L, Kim PY, Gombos DS, Kawedia JD, Komaki R, Gomez DR, Nguyen QN, O'Reilly MS, Lu C, Fossella FV, Skoulidis F, Zhang J, Tsao AS, Heymach JV, Blumenschein GRCancer treatment and research communicationsPhase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer. Cancer Treat Res Commun. 2022; 30:100514.Cancer Treat Res Commun2022-01-07T00:00:002022Phase I Trial of Definitive Concurrent Chemoradiotherapy and Trametinib for KRAS-Mutated Non-Small Cell Lung Cancer.Authorship 10432718Authorship 10444214135367910Scherpereel A, Antonia S, Bautista Y, Grossi F, Kowalski D, Zalcman G, Nowak AK, Fujimoto N, Peters S, Tsao AS, Mansfield AS, Popat S, Sun X, Lawrance R, Zhang X, Daumont MJ, Bennett B, McKenna M, Baas PLung cancer (Amsterdam, Netherlands)First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. Lung Cancer. 2022 05; 167:8-16.Lung Cancer2022-03-21T00:00:002022First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.35462085Carbone M, Pass HI, Ak G, Alexander HR, Baas P, Baumann F, Blakely AM, Bueno R, Bzura A, Cardillo G, Churpek JE, Dianzani I, De Rienzo A, Emi M, Emri S, Felley-Bosco E, Fennell DA, Flores RM, Grosso F, Hayward NK, Hesdorffer M, Hoang CD, Johansson PA, Kindler HL, Kittaneh M, Krausz T, Mansfield A, Metintas M, Minaai M, Mutti L, Nielsen M, O'Byrne K, Opitz I, Pastorino S, Pentimalli F, de Perrot M, Pritchard A, Ripley RT, Robinson B, Rusch V, Taioli E, Takinishi Y, Tanji M, Tsao AS, Tuncer AM, Walpole S, Wolf A, Yang H, Yoshikawa Y, Zolondick A, Schrump DS, Hassan RJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerMedical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. J Thorac Oncol. 2022 07; 17(7):873-889.J Thorac Oncol2022-04-21T00:00:002022Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations.Authorship 10504122635820397Elamin YY, Robichaux JP, Carter BW, Altan M, Tran H, Gibbons DL, Heeke S, Fossella FV, Lam VK, Le X, Negrao MV, Nilsson MB, Patel A, Vijayan RSK, Cross JB, Zhang J, Byers LA, Lu C, Cascone T, Feng L, Luthra R, San Lucas FA, Mantha G, Routbort M, Blumenschein G, Tsao AS, Heymach JVCancer cellPoziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell. 2022 07 11; 40(7):754-767.e6.Cancer Cell2022-07-11T00:00:002022Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity.Authorship 105683818Authorship 10607721636087590Hui D, Puac V, Shelal Z, Dev R, Hanneman SK, Jennings K, Ma H, Urbauer DL, Shete S, Fossella F, Liao Z, Blumenschein G, Chang JY, O'Reilly M, Gandhi SJ, Tsao A, Mahler DA, Bruera EThe Lancet. OncologyEffect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial. Lancet Oncol. 2022 10; 23(10):1321-1331.Lancet Oncol2022-09-07T00:00:002022Effect of dexamethasone on dyspnoea in patients with cancer (ABCD): a parallel-group, double-blind, randomised, controlled trial.36371941Liu Y, Yao L, Kalhor N, Carter BW, Altan M, Blumenschein G, Byers LA, Fossella F, Gibbons DL, Kurie JM, Lu C, Skoulidis F, Chang JY, Liao Z, Gomez DR, O'Reilly M, Heymach JV, Tsao AS, Lin SHLung cancer (Amsterdam, Netherlands)Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer. 2022 Oct 29; 174:112-117.Lung Cancer2022-10-29T00:00:002022Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial.Authorship 1063019636737380Zhou N, Bell CS, Feldman HA, Haymaker CL, Hofstetter WL, Tsao AS, Mehran RJ, Rice DC, Sepesi B, Mesothelioma Immune Genomic GroupThe Journal of thoracic and cardiovascular surgeryTumor thickness in mesothelioma predicts differential response to neoadjuvant therapy and survival. J Thorac Cardiovasc Surg. 2023 08; 166(2):362-371.e9.J Thorac Cardiovasc Surg2022-12-14T00:00:002022Tumor thickness in mesothelioma predicts differential response to neoadjuvant therapy and survival.Authorship 106567224Authorship 10656411036925644Negrao MV, Papadimitrakopoulou VA, Price AC, Tam AL, Furqan M, Laroia ST, Massarelli E, Pacheco J, Heymach JV, Tsao AS, Walker GV, Vora L, Mauro D, Kelley H, Wooldridge JE, Krieg AM, Niu JJTO clinical and research reportsVidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients?With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC. JTO Clin Res Rep. 2023 Mar; 4(3):100423.JTO Clin Res Rep2022-10-26T00:00:002022Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients?With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade-Resistant Advanced NSCLC.36928818Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, Godoy MCB, Feldman H, William WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Blumenschein G, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi BNature medicineNeoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023 03; 29(3):593-604.Nat Med2023-03-16T00:00:002023Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial.Authorship 1072740637270692Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal E, Offin M, Provencio M, Clarke J, Hussain M, Otterson GA, Dagogo-Jack I, Goldman JW, Morgensztern D, Alcasid A, Usari T, Wissel P, Wilner K, Pathan N, Tonkovyd S, Johnson BEJournal of clinical oncology : official journal of the American Society of Clinical OncologyPhase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer. J Clin Oncol. 2023 07 20; 41(21):3700-3711.J Clin Oncol2023-06-04T00:00:002023Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer.Authorship 10750231537478883Chang JY, Lin SH, Dong W, Liao Z, Gandhi SJ, Gay CM, Zhang J, Chun SG, Elamin YY, Fossella FV, Blumenschein G, Cascone T, Le X, Pozadzides JV, Tsao A, Verma V, Welsh JW, Chen AB, Altan M, Mehran RJ, Vaporciyan AA, Swisher SG, Balter PA, Fujimoto J, Wistuba II, Feng L, Lee JJ, Heymach JVLancet (London, England)Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023 09 09; 402(10405):871-881.Lancet2023-07-18T00:00:002023Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial.Authorship 107750113Authorship 10778512037637041Deboever N, Zhou N, McGrail DJ, Tomczak K, Oliva JL, Feldman HA, Parra E, Zhang J, Lee PP, Antonoff MB, Hofstetter WL, Mehran RJ, Rajaram R, Rice DC, Roth JA, Swisher SS, Vaporciyan AA, Altan M, Weissferdt A, Tsao AS, Haymaker CL, Sepesi BFrontiers in oncologyRadiographic response to neoadjuvant therapy in pleural mesothelioma should serve as a guide for patient selection for cytoreductive operations. Front Oncol. 2023; 13:1216999.Front Oncol2023-08-11T00:00:002023Radiographic response to neoadjuvant therapy in pleural mesothelioma should serve as a guide for patient selection for cytoreductive operations.37649681Wang K, Du R, Roy-Chowdhuri S, Li ZT, Hong L, Vokes N, Elamin YY, Hume CB, Skoulidis F, Gay CM, Blumenschein G, Fossella FV, Tsao A, Zhang J, Karachaliou N, O'Brate A, Gann CN, Lewis J, Rinsurongkawong W, Lee JJ, Gibbons DL, Vaporciyan AA, Heymach JV, Altan M, Le XJTO clinical and research reportsBrief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC. JTO Clin Res Rep. 2023 Aug; 4(8):100533.JTO Clin Res Rep2023-06-01T00:00:002023Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC.Authorship 1083865938012986Wang K, Du R, Myall NJ, Lewis WE, Uy N, Hong L, Skoulidis F, Byers LA, Tsao A, Cascone T, Pozadzides J, Tu J, Negrao MV, Gibbons DL, Park K, Rinsurongkawong W, Lee JJ, Gandara D, Behl D, Shu CA, Riess JW, Baik C, Wakelee HA, Vaporciyan AA, Heymach JV, Zhang J, Le XJournal of thoracic oncology : official publication of the International Association for the Study of Lung CancerReal-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol. 2024 Mar; 19(3):500-506.J Thorac Oncol2023-11-25T00:00:002023Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC.Authorship 10889186Authorship 108873819Authorship 10889251638357092Zhang B, Lewis W, Stewart CA, Morris BB, Solis LM, Serrano A, Xi Y, Wang Q, Lopez ER, Concannon K, Heeke S, Tang X, Raso G, Cardnell RJ, Vokes N, Blumenschein G, Elamin Y, Fosella F, Tsao A, Skoulidis F, Hume CB, Sasak K, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Tran H, Zhang J, Gibbons D, Vaporciyan A, Wang J, Park K, Heymach JV, Byers LA, Gay CM, Le XJTO clinical and research reportsBrief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic?Targets. JTO Clin Res Rep. 2024 Feb; 5(2):100623.JTO Clin Res Rep2023-12-17T00:00:002023Brief Report: Comprehensive Clinicogenomic Profiling of Small Cell Transformation From EGFR-Mutant NSCLC Informs Potential Therapeutic?Targets.38357801Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal E, Offin M, Provencio M, Clarke J, Hussein M, Otterson GA, Dagogo-Jack I, Goldman JW, Morgensztern D, Alcasid A, Usari T, Wissel P, Wilner K, Pathan N, Tonkovyd S, Johnson BEFuture oncology (London, England)A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer. Future Oncol. 2024 Feb 15.Future Oncol2024-02-15T00:00:002024A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer.38358753Szlosarek PW, Creelan BC, Sarkodie T, Nolan L, Taylor P, Olevsky O, Grosso F, Cortinovis D, Chitnis M, Roy A, Gilligan D, Kindler H, Papadatos-Pastos D, Ceresoli GL, Mansfield AS, Tsao A, O'Byrne KJ, Nowak AK, Steele J, Sheaff M, Shiu CF, Kuo CL, Johnston A, Bomalaski J, Zauderer MG, Fennell DA, ATOMIC-Meso Study GroupJAMA oncologyPegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial. JAMA Oncol. 2024 Feb 15.JAMA Oncol2024-02-15T00:00:002024Pegargiminase Plus First-Line Chemotherapy in Patients With Nonepithelioid Pleural Mesothelioma: The ATOMIC-Meso Randomized Clinical Trial.Authorship 1090279238447258Wright C, Tsao A, Triller M, Hagberg CJournal of clinical anesthesiaNavigating professionalism challenges: Impact on patient safety. J Clin Anesth. 2024 Mar 05; 95:111427.J Clin Anesth2024-03-05T00:00:002024Navigating professionalism challenges: Impact on patient safety.true1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessor